Table 1. Univariate and multivariate survival analysis of patients with CC including CDKN3 expression, clinical stage and HPV type.
| Variable | n | Univariate (HR) a | p b | Confidence Interval 95% | Multivariate (HR) c | p b | Confidence Interval 95% |
|---|---|---|---|---|---|---|---|
| CDKN3 expression (FC) d | |||||||
| Low (< 17) | 99 | 1 | 1 | ||||
| High (≥ 17) | 22 | 5 | 3.3 x 10−6 | 2.5–10.0 | 3.3 | 9.2 x 10−4 | 1.6–6.8 |
| FIGO | |||||||
| IB1/IB2 | 65 | 1 | 1 | ||||
| IIA/IIB | 42 | 4.1 | 1.0 x 10−3 | 1.8–9.3 | 3.1 | 9.6 x 10−3 | 1.3–7.3 |
| IIIB/IVB | 14 | 6.9 | 1.2 x 10−4 | 2.6–18.4 | 4.5 | 3.9 x 10−3 | 1.6–12.7 |
| Viral type | |||||||
| HPV16 | 83 | 1 | |||||
| Other HPVs e | 38 | 0.6 | 1.9 x 10−1 | 0.3–1.3 |
a. Unadjusted Hazard Ratio. Univariate analysis was performed for each variable.
b. Cox proportional hazards model.
c. Adjusted Hazard Ratio. Multivariate analysis was performed considering CDKN3 expression (FC) and FIGO.
d. FC, fold change, expression of CDKN3 in tumors in relation to the mean in the control group.
e. Positive tumors for HPVs 18, 31, 33, 35, 45, 51, 52, 53, 58, 59 and 68.